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Introduction
============

Techniques for identifying white matter tracts have existed for decades \[[@REF1]\]; however, traditional (ie, manual) tractography has several limitations which hinder its routine application. With manual tractography, a fiber tract is localized first by selecting specific regions of interest (ROI) that are thought to be along the course of the intended white matter tract. These ROIs are defined by anatomical reference points, and it is from these regions that white matter fiber tracts are derived. Consequently, manual tractography is limited by its prolonged workflow, user bias, and anatomical distortions which may further compound human error \[[@REF2]\]. This is problematic because the applicability of tractography for a neurosurgeon is to help identify essential white matter tracts that may be around a potentially resectable lesion, such as a tumor, which by its very nature will have distorted anatomy \[[@REF3]\]. Given these limitations, white matter tractography has been utilized infrequently and with skepticism in general practice.

New technologies have recently emerged which seem to have overcome the intrinsic limitations of manual tractography. Advancements in automating tract-based analysis of diffusion tensor imaging (DTI) obtained with magnetic resonance imaging (MRI) have dramatically cut the labor and time required for tractography acquisition, as well as improved reliability and validity \[[@REF4]\]. With the automated algorithm, diffusion tensor data from each voxel of a brain MRI are combined to extrapolate the major tract bundles\--thereby identifying the theoretical end of fiber tracts by localizing the points of lowest anisotropy. Ultimately, this generates an accurate picture of major white matter tracts in the brain, an approach known formally as automated whole brain tractography (AWBT). AWBT stands in stark contrast to manual tractography, which is labor intensive, intrinsically bias prone, and can only capture one tract at a time between predetermined ROIs \[[@REF5]\].

AWBT has the potential to garner widespread use with its ease of implementation and intuitive integration with stereotactic neuronavigation. We describe herein our case series of patients in which AWBT augmented our presurgical planning as well as intraoperative extent of resection. In addition, we also present two illustrative cases where AWBT was foundational to presurgical planning, surgical decisions, and ultimately patient outcomes.

Case presentation
=================

Under a previously approved institutional review board (IRB \#9755) study designed to examine the outcomes in craniotomies for tumor resection, we retrospectively reviewed the most recent patients in whom AWBT was utilized. We identified 73 consecutive patients that underwent open surgical resection of an intracranial tumor using the Synaptive Brightmatter™ System (Synaptive Medical, Toronto, Canada) between July 2016 to July 2017. All patients underwent conventional anatomic MRI with and without contrast sequences in addition to DTI on a 3 Tesla MRI scanner (Ingenia 3.0T, Philips, Amsterdam NL). Post-hoc AWBT processing was performed on a separate PC workstation using BrightMatter software (Synaptive Medical, Toronto Canada). Final patient registration to the navigation system occurred immediately preoperatively and was confirmed again during surgery using anatomic landmarks. We divided patients into those that had undergone mapping (either language or motor) and those that did not. In both sets of patients, we reported patient age at the time of surgery, gender, specific procedure performed, laterality of the procedure, depth of resection from cortical surface, and the smallest distance between the lesion and directly adjacent eloquent white matter tracts. All mapping surgeries were performed by two board certified neurosurgeons who specialize in oncologic surgery and are experienced in mapping. In our institution, we routinely perform tractography for lesions directly abutting major white matter tracts (i.e., the corticospinal tract, the superior longitudinal fasciculus, and the arcuate fasciculus). Student's unpaired t-test and Fisher's exact test were used to compare variables when appropriate. Outcomes, including temporary and permanent neurological outcomes, were also reported based on in-depth chart review of individual hospital courses. A temporary deficit was defined as a change in the neurological examination that returned to preoperative baseline within three months. Any persistent changes from baseline, whether anticipated or unanticipated, were considered permanent.

Results

Of the 73 total patients, 28 underwent either speech or motor mapping with AWBT (Table [1](#TAB1){ref-type="table"}) and 45 utilized AWBT alone (Table [2](#TAB2){ref-type="table"}). Specific demographics and comparison statistics between each group can be found in Table [3](#TAB3){ref-type="table"}. When comparing the two groups of patients, there was no statistically significant difference in age, gender, laterality of surgery, and whether the surgery was a revision. Patients that underwent mapping did not have lesions of different depths; however, they did have lesions that were significantly closer to specific white matter tracts, namely the corticospinal \[p \< 0.0001\], superior longitudinal fasciculus \[p \< 0.0001\], or arcuate fasciculus \[p = 0.004\]. This makes sense intuitively, as patients who require supplementary mapping are thought to have higher risk lesions that are in close proximity to eloquent areas, such as white matter tracts, and therefore benefit from the additional protection of mapping. While there was no statistical difference in neurological deficit after surgery between mapping and non-mapping cases (p = 0.772), patients who underwent mapping had a higher rate of postoperative recovery (p = 0.041). This finding is crucial as, despite the notion that these patients have higher risk surgeries, they are at no increased risk for postoperative deficits and are more likely to recover after a deficit. This further signifies that healthy perilesional tissue was not irreversibly damaged.

###### Patients Who Underwent Speech and/or Motor Mapping

WHO: World Health Organization

CST: Corticospinal Tract

SLF: Superior Longitudinal Fasciculus

AF: ​Arcuate Fasciculus

Oligo: Oligodendroglioma

MM: Millimeters

Pt: Patient

  ------- ----- ----- ------- ------------------- ------------------ ------------ ----------- ------------------------- ------------- ------------- ------------ -------------------- ------------------------------- -------------------------------------------- -----------------
  Pt \#   Age   Sex   Side    Craniotomy          Revision Surgery   Speech Map   Motor Map   Depth of Resection (MM)   MM From CST   MM from SLF   MM from AF   New Postop Deficit   Deficit Recovery within 3 mo?   Histology                                    Major Morbidity
  1       75    M     Left    Parietal            No                 Yes          No          31                        19.6          2             2            No                                                   Glioblastoma                                 None
  2       70    M     Right   Frontal             Yes                Yes          Yes         14.2                      0             17.1          22.1         No                                                   Metastatic Squamous Cell                     None
  3       45    F     Right   Fronto-parietal     Yes                No           Yes         32.7                      0             11.3          13.2         Yes                  Yes                             Metastatic Poorly Differentiated Carcinoma   None
  4       31    F     Right   Frontal             Yes                No           Yes         47.4                      28.6          24.5          30.2         No                                                   Anaplastic Astrocytoma                       None
  5       26    M     Right   Parietal            No                 No           Yes         54.5                      0             13            15           No                                                   Glioblastoma                                 None
  6       29    M     Right   Frontal             Yes                Yes          Yes         37.5                      12.3          17.3          8.6          No                                                   Oligo                                        None
  7       26    M     Left    Fronto-temporal     No                 Yes          Yes         40.6                      0             0             0            Yes                  No                              Glioblastoma                                 None
  8       36    M     Left    Frontal             Yes                Yes          Yes         60.5                      8             0             5.3          No                                                   Glioblastoma                                 None
  9       53    F     Left    Temporal            Yes                Yes          No          28                        24.3          0             0            Yes                  Yes                             Anaplastic Oligo                             None
  10      38    F     Right   Parietal            Yes                No           Yes         24.5                      16.7          23.7          18.5         No                                                   Oligo                                        None
  11      67    F     Left    Parietal            No                 No           Yes         68.3                      5             0             0            No                                                   Glioblastoma                                 None
  12      55    M     Left    Fronto-parietal     Yes                Yes          Yes         35.1                      0             0             0            No                                                   Glioblastoma                                 None
  13      26    F     Left    Parietal            No                 Yes          Yes         48.6                      0             0             0            No                                                   Astrocytoma                                  None
  14      65    M     Right   Parietal            No                 No           Yes         57.8                      0             0             16.6         Yes                  No                              Metastatic Poorly Differentiated Carcinoma   None
  15      44    M     Right   Parietal            Yes                No           Yes         41.1                      0             18.7          0            No                                                   Glioblastoma                                 None
  16      64    M     Right   Frontal             No                 No           Yes         39                        14.7          8.9           14           No                                                   Glioblastoma                                 None
  17      73    F     Left    Parietal            No                 No           Yes         39.6                      0             0             24.1         No                                                   Radiation Necrosis                           None
  18      32    M     Right   Frontal             No                 Yes          Yes         97                        0             0             0            No                                                   Glioblastoma                                 None
  19      62    M     Right   Fronto-parietal     No                 No           Yes         40.4                      0             11.3          18.3         No                                                   Glioblastoma                                 None
  20      66    M     Right   Fronto-parietal     Yes                No           Yes         50.4                      0             0             0            No                                                   Glioblastoma                                 None
  21      76    F     Left    Frontal             Yes                No           Yes         54.9                      0             0             18.1         No                                                   Glioblastoma                                 None
  22      62    F     Left    Parietal            Yes                No           Yes         74.8                      0             0             0            No                                                   Glioblastoma                                 None
  23      26    F     Left    Temporal-Parietal   No                 Yes          Yes         41.3                      41            11.4          0            Yes                  Yes                             Anaplastic Oligo                             None
  24      63    M     Left    Frontal             Yes                No           Yes         20.6                      0             14.3          33.8         Yes                  Yes                             Anaplastic Astrocytoma                       None
  25      48    M     Right   Frontal             No                 No           Yes         68.8                      0             0             42           Yes                  Yes                             Glioblastoma                                 None
  26      76    M     Left    Temporal            No                 Yes          No          53.4                      25            36.1          0            No                                                   Glioblastoma                                 None
  27      70    M     Right   Parietal            No                 No           Yes         41.8                      0             0             19.8         No                                                   Glioblastoma                                 None
  28      45    F     Right   Parietal            No                 No           Yes         41.7                      10.5          26.8          15           No                                                   Glioblastoma                                 None
  ------- ----- ----- ------- ------------------- ------------------ ------------ ----------- ------------------------- ------------- ------------- ------------ -------------------- ------------------------------- -------------------------------------------- -----------------

###### Patients Who Did Not Undergo Mapping

WHO: World Health Organization

CST: Corticospinal Tract

SLF: Superior Longitudinal Fasciculus

AF: ​Arcuate Fasciculus

Oligo: Oligodendroglioma

MM: Millimeters

Pt: Patient

  ------- ----- ----- ----------- ------------------- ------------------ ------------------------- ------------- ------------- ------------ -------------------- ------------------------------- -------------------------------------------- --------------------------
  Pt \#   Age   Sex   Side        Craniotomy          Revision Surgery   Depth of Resection (MM)   MM From CST   MM from SLF   MM from AF   New Postop Deficit   Deficit Recovery within 3 mo?   Histology                                    Major Morbidity
  1       55    M     Left        Parietal            Yes                12.2                      30            15            15           No                                                   Metastatic Squamous Cell                      
  2       45    M     Right       Parietal            No                 76.4                      36            0             0            Yes                  No                              Glioblastoma                                 Intracerebral hemorrhage
  3       54    F     Left        Frontal             No                 68                        3.5           3             15           Yes                  No                              Glioblastoma                                 Intracerebral hemorrhage
  4       46    M     Right       Fronto-temporal     No                 37.1                      18            8.6           10           No                                                   Glioblastoma                                  
  5       46    M     Left        Temporal-Parietal   No                 51.2                      8.3           11.4          9.8          No                                                   Atypical Meningioma                           
  6       70    M     Left        Fronto-temporal     No                 50.3                      22            26.8          26.8         No                                                   Meningioma                                    
  7       36    F     Left        Temporal            No                 40                        25.7          20.8          13           No                                                   Anaplastic Astrocytoma                        
  8       56    M     Left        Parietal            Yes                37.7                      0             9.6           10           No                                                   Reactive Changes                              
  9       55    M     Left        Parietal            Yes                52.3                      34.5          10.7          13.9         No                                                   Reactive Changes                              
  10      55    F     Left        Temporal            No                 52.6                      15.9          16.4          15.9         No                                                   Glioblastoma                                  
  11      74    M     Right       Temporal            No                 34.3                      36.2          28.2          28.2         No                                                   Glioblastoma                                  
  12      64    M     Bilateral   Bicoronal           No                 48.8                      70.1          44.5          83.4         Yes                  No                              Atypical Meningioma                          Intracerebral hemorrhage
  13      57    M     Left        Frontal             Yes                69.2                      21.2          33.3          35.8         No                                                   Glioblastoma                                  
  14      63    F     Left        Temporal            No                 22.3                      30.5          20.3          16.4         No                                                   Anaplastic Astrocytoma                        
  15      61    M     Left        Parietal            No                 76.1                      0             0             0            No                                                   Glioblastoma                                  
  16      69    M     Right       Suboccipital        No                 49.2                      10.6          60.9          53.4         No                                                   Metastatic Adenocarcinoma                     
  17      55    M     Bilateral   Bicoronal           No                 91.5                      17.9          17.2          22.3         No                                                   Metastatic Melanoma                           
  18      53    F     Left        Fronto-temporal     No                 41.7                      30.1          40.5          52.3         No                                                   Meningioma                                    
  19      48    M     Left        Temporal            No                 40.3                      36.1          36.6          26.4         No                                                   Glioblastoma                                  
  20      52    M     Right       Temporal            Yes                12.8                      37            27.8          14.6         No                                                   Glioblastoma                                  
  21      71    F     Right       Frontal             No                 73.5                      15.1          0             37.3         No                                                   Glioblastoma                                  
  22      38    M     Left        Parietal            Yes                44.1                      0             12.4          10.1         No                                                   Astrocytoma                                   
  23      54    M     Right       Temporal            Yes                32                        0             11.2          0            No                                                   Diffuse Large B-Cell Lymphoma                 
  24      48    F     Right       Temporal            No                 56.8                      0             14.8          0            Yes                  No                              Anaplastic Astrocytoma                        
  25      60    F     Left        Temporal            Yes                40.3                      18.5          30.4          16.6         Yes                  No                              Gliosarcoma                                   
  26      48    F     Left        Fronto-temporal     No                 31.5                      19            40.9          52.1         No                                                   Meningioma                                    
  27      55    F     Right       Fronto-temporal     No                 16.9                      13.3          16.9          18.7         Yes                  Yes                             Metastatic Adenocarcinoma                     
  28      56    M     Right       Temporal            Yes                31                        14.5          43.2          11.7         No                                                   Glioblastoma                                  
  29      73    F     Left        Occipital           No                 26.1                      51.6          22.6          23.4         Yes                  No                              Glioblastoma                                 Intracerebral hemorrhage
  30      57    M     Left        Parietal            No                 49                        17.2          13.1          18.7         Yes                  Yes                             Metastatic Small Cell Carcinoma               
  31      45    F     Right       Temporal            No                 44.3                      42.7          17.8          32.5         No                                                   Oligo                                         
  32      54    M     Right       Parietal            Yes                35.7                      36.7          22.6          10.9         No                                                   Glioblastoma                                  
  33      77    M     Right       Temporal            No                 44.3                      25            31            12.6         No                                                   Glioblastoma                                  
  34      55    M     Right       Temporal            No                 38.5                      36.7          35.7          0            No                                                   Anaplastic Astrocytoma                        
  35      53    M     Left        Frontal             Yes                74.2                      7.3           21.1          53.2         No                                                   Glioblastoma                                  
  36      63    F     Left        Frontal             No                 37.8                      47            9.4           62.1         No                                                   Meningioma                                    
  37      42    M     Right       Frontal             Yes                34.3                      31            6.3           21           No                                                   Oligo                                         
  38      71    M     Left        Temporal            No                 50.6                      26.4          36            10.7         No                                                   Glioblastoma                                  
  39      55    M     Right       Temporal-Parietal   No                 19.1                      43.9          31.9          32.2         No                                                   Meningioma                                    
  40      46    M     Right       Occipital           Yes                40.9                      59.8          29.8          18.9         No                                                   Glioblastoma                                  
  41      27    M     Right       Frontal             Yes                71.4                      0             0             0            No                                                   Glioblastoma                                  
  42      58    F     Left        Frontal             No                 31                        41.4          15.7          24.8         No                                                   Metastatic Poorly Differentiated Carcinoma    
  43      86    M     Left        Occipital           No                 84.5                      24.2          36.4          16.6         Yes                  No                              Glioblastoma                                  
  44      59    M     Right       Parietal            No                 52.3                      41.7          19.1          0            No                                                   Glioblastoma                                  
  45      60    F     Right       Occipital           Yes                43                        45.4          32.4          37.3         No                                                   Glioblastoma                                  
  ------- ----- ----- ----------- ------------------- ------------------ ------------------------- ------------- ------------- ------------ -------------------- ------------------------------- -------------------------------------------- --------------------------

###### Comparative Statistics

Student's unpaired t-test and Fisher's exact test were used to compare variables when appropriate. 

\* signifies statistically significant results, and include CST distance, SLF distance, arcuate fasciculus distance, and deficit recovery after surgery.​

CST: corticospinal tract; GBM: glioblastoma; SD: standard deviation; SLF: superior longitudinal fasciculus

  ---------------------------------- ----------------- ----------- -------------------- ------- ------------- --- -------------
                                     With Monitoring               Without Monitoring                             
  Age                                                                                                              
  Mean (SD)                          51.75             (17.78)                          56.11   (11.23)           p=0.252
  Median (Range)                     54                (26-76)                          55      (27-86)            
  Sex (%)                                                                                                          
  Male                               17                (60.71%)                         30      (66.67%)          p=0.624
  Female                             11                (39.29%)                         15      (33.33%)           
  Laterality (%)                                                                                                   
  Left                               13                (46.43%)                         23      (51.11%)          p=0.631
  Right                              15                (53.57%)                         20      (44.44%)           
  Bicoronal                          0                 (0.00%)                          2       (4.44%)            
  Revision (%)                       13                (46.43%)                         15      (33.33%)          p=0.325
  Speech Mapping (%)                 11                (39.29%)                                                    
  Motor Mapping (%)                  25                (89.29%)                                                    
  Both (%)                           8                 (28.57%)                                                    
  Depth of Resection (mm)                                                                                          
  Mean (SD)                          45.91             (17.53)                          45.94   (18.70)           p=0.995
  Median (Range)                     41.5              (14.2-97)                        43      (12.2-91.5)        
  CST Distance (mm)                                                                                                
  Mean (SD)                          7.35              (11.28)                          25.38   (17.03)           p\<0.0001\*
  Median (Range)                     0                 (0-41)                           25      (0-70.1)           
  SLF Distance (mm)                                                                                                
  Mean (SD)                          8.44              (10.49)                          21.83   (13.84)           p\<0.0001\*
  Median (Range)                     1                 (0-36.1)                         20.3    (0-60.9)           
  Arcuate Fasciculus Distance (mm)                                                                                 
  Mean (SD)                          11.31             (12.03)                          21.86   (18.46)           p\<0.004\*
  Median (Range)                     10.9              (0-42)                           16.6    (0-83.4)           
  Deficit (%)                        7                 (25.00%)                         9       (20.00%)          p=0.772
  Deficit Recovery (%)               6                 (85.71%)                         2       (22.22%)          p=0.041\*
  GBM (%)                            17                (60.71%)                         21      (46.67%)          p=0.336
  Meningioma (%)                     0                 (0.00%)                          7       (15.56%)           
  Metastasis (%)                     3                 (10.71%)                         6       (13.33%)           
  Astrocytoma (%)                    3                 (10.71%)                         5       (11.11%)           
  Oligodendroglioma (%)              4                 (14.29%)                         2       (4.44%)            
  Other (%)                          1                 (3.57%)                          4       (8.89%)            
  ---------------------------------- ----------------- ----------- -------------------- ------- ------------- --- -------------

The clinical utility of AWBT is best illustrated through specific case examples. We present two patient vignettes that demonstrate the notable impact of AWBT on the ultimate treatment strategy, whether by affecting presurgical planning, intraoperative surgical decision making, and/or by helping localize white matter tracts.

Case 1

A 28-year-old female with a known history of anaplastic ependymoma (World Health Organization Grade III), which included two prior surgical resections and stereotactic radiosurgical treatment, presented with worsening left-hand paresis with loss of dexterity. An MRI of the brain with and without contrast demonstrated a 4-cm cystic lesion in the right frontal lobe with a focal nodule of enhancement at the medial border of the lesion (Figures [1A](#FIG1){ref-type="fig"}-[1B](#FIG1){ref-type="fig"}). Calling on a priori knowledge of conventional sulcal anatomy, it was initially thought that this convexity lesion was displacing the corticospinal tracts (CSTs) posteriorly and medially. Since this was a superficial lesion, an anterior approach would be possible with caution being taken when dissecting at the lateral and posterior margins.

![MRI of the brain and automated whole brain tractography (AWBT) for Case 1\
A) Axial MRI of the brain with contrast showing a right-sided mass, denoted by a red arrow. B) Sagittal MRI of the brain with contrast showing a right-sided mass, denoted by a red arrow. C) AWBT image showing the tumor to be sitting within the corticospinal tract. D) AWBT image showing the tumor (denoted by red arrow), sitting within the corticospinal tract (denoted by yellow arrow).\
AWBT: automated whole brain tractography; MRI: magnetic resonance imaging](cureus-0009-00000001656-i01){#FIG1}

AWBT revealed that the lesion sat within and also divided the CSTs (Figures [1C](#FIG1){ref-type="fig"}-[1D](#FIG1){ref-type="fig"}), and it was clear the previous surgical plan to enter the lesion anteriorly could jeopardize motor function. The surgical plan was modified whereby the lesion would be entered directly. The patient underwent an awake, right frontal craniotomy with intraoperative MRI and motor mapping, given that the AWBT demonstrated intimate proximity between the tumor and the CSTs. The reconstructed tractography data was fused with T1 MRI post-contrast imaging for stereotactic intraoperative neuronavigation. Cortical mapping was used to identify functional tissue as well as the boundaries of the lesion. Intraoperative mapping validated the tractography data - the lesion was embedded within the CST. Resection was undertaken in an en-bloc fashion with subsequent subcortical stimulation of the resection borders. In the deep posterior lateral border of the surgical cavity, left upper extremity motor responses were elicited consistently down to 4mAmp (Ojemann Cortical Stimulator, Integra Lifesciences, Plainsboro, NJ). This stimulation correlated well with tractography fused neuronavigation, again confirming the accuracy of AWBT. Postoperatively, the patient had no change in her neurological examination, despite surgery between the fibers of the CST. A postoperative MRI confirmed a gross total resection of the lesion. Pathology again revealed anaplastic ependymoma. Her hospital course was uneventful and she was discharged home on postoperative day 3. Over long-term follow-up, the patient remained neurologically unchanged.

Case 2

A 44-year-old male with a known history of right parietal glioblastoma multiforme (World Health Organization Grade IV), which included post-subtotal resection, external beam radiation therapy, and adjuvant chemotherapy, presented to the clinic with an MRI demonstrating possible recurrence of disease (Figures [2A](#FIG2){ref-type="fig"}-[2B](#FIG2){ref-type="fig"}). AWBT showed that the tumor was lateral and adjacent to the CSTs, which allowed for surgery using a lateral approach (Figures [2C](#FIG2){ref-type="fig"}-[2D](#FIG2){ref-type="fig"}). AWBT showed close proximity of the descending corticospinal tract (CST) to the lesion, and the decision was made for the patient to undergo a right parietal craniotomy with intraoperative neurophysiological monitoring using motor-evoked potentials and subcortical stimulation. This was paramount for safe removal of the tumor during the deep and medial portion of the resection.

![MRI of the brain and automated whole brain tractography(AWBT) for Case 2\
A) Axial MRI of the brain with contrast showing a right-sided mass (denoted by red arrow). B) Sagittal MRI of the brain with contrast showing a right-sided mass (denoted by red arrow). C) AWBT image showing the tumor to be sitting deep and adjacent to the corticospinal tract. D) AWBT image showing the tumor (denoted by red arrow), sitting adjacent to the deep portions of the corticospinal tract (denoted by yellow arrow).\
AWBT: automated whole brain tractography; MRI: magnetic resonance imaging](cureus-0009-00000001656-i02){#FIG2}

The stereotactic wand fused with AWBT was used to determine the optimal corticectomy site, and the tumor was removed in a piecemeal fashion via an intralesional approach. Upon approaching the deep margin of the tumor, subcortical stimulation was correlated with AWBT to localize the CST. Continued careful resection was undertaken until normal-appearing tissue was encountered. AWBT neuronavigation confirmed that the CST was deep to the resection cavity. This correlated accurately with subcortical stimulation of 10mAmp, implying a distance of at most 1 cm to the CST. Postoperatively, the patient maintained a stable neurological examination, with a postoperative MRI showing complete resection at the deep margins of the lesion adjacent to the CST. Pathology again showed glioblastoma multiforme. His hospital course was uneventful, and he was discharged home on postoperative day 2.

Discussion
==========

The goals of neuro-oncologic surgery are cytoreduction, tissue sampling, and reduction of mass effect, all while preserving functional perilesional brain. Unfortunately, in neurological surgery, the separation between tumor and functional tissue can be difficult to ascertain. This is particularly true with essential white matter tracts, such as the corticospinal tract (responsible for motor function) and the arcuate fasciculus (essential for language) \[[@REF2]\]. It is only recently that AWBT has come to fruition, allowing these tracts to be reliably and accurately identified without bias and within a clinically applicable timespan \[[@REF6]\]. This accomplishment has overcome a historical workflow limitation and made individualized tractography relatively easy to implement.

In this study, we show that patients who were selected to undergo mapping had lesions closer to essential white matter tracts, including the corticospinal tract, superior longitudinal fasciculus, and the arcuate fasciculus. We also found that while patients who underwent mapping had the same risk of postoperative deficit as non-mapping patients, they were more likely to have postoperative recovery of their neurological deficit. This is a counter-intuitive result, given that even though this population of patients had lesions that were closer to eloquent white matter tracts (and thus considered high risk), they had a better overall outcome with mapping than patients with lesions at low risk for iatrogenic injury. While it may be argued that patients who require mapping for tumors are a different surgical population than patients who do not, we think comparisons between these two populations are appropriate. These two populations of patients are naturally separated into 'low-risk' and 'high-risk' groups for iatrogenic injury, with mapping as an extra precaution for patients who are high-risk (their lesions were significantly closer to eloquent white matter structures). Our institute also has a traditionally low threshold for mapping, implying that the non-mapping patients were very unlikely to have an injury. Despite this, both populations had the same rate of postoperative deficit, and the high-risk population had only a transient deficit. This helps to illustrate that while AWBT is a useful adjunct, it cannot replace the gold standard of mapping for high-risk lesions intraoperatively; however, AWBT can be used to help decide which patients are more appropriate for mapping, and thus contributing to increased postoperative recovery by identifying patients who have lesions near previously unseen essential white matter tracts.

While AWBT is a significant improvement to manual tractography, it is still subject to the limitations inherent in all tractography. Peritumoral edema disrupts the fractional anisotropy that DTI uses to clarify white matter tracts. Crossing fibers may be difficult to isolate due to their low anisotropy \[[@REF9]\] and intraoperative brain shift may provide inaccurate localization data \[[@REF10]\].

Given our strong caseload of examples where AWBT affected surgical decision making by localizing previously invisible white matter tracts, combined with how easy it is to obtain, AWBT is now considered for all patients who are undergoing intracerebral tumor resection. For lesions near eloquent brain structures, AWBT has become the standard of care at our hospital. While our findings agree with those of comparable single-center series \[[@REF7]-[@REF8]\], prospective studies are necessary to show how AWBT can improve clinical decision making to further support its use as a mainstay for surgery in eloquent areas.

Conclusions
===========

While the current gold standard for localization of speech and language function remains direct cortical and subcortical stimulation, AWBT can provide critical preoperative and intraoperative information for the neurosurgeon. Our recent experience highlights the utility of AWBT in select cases of tumors near eloquent structures, and we provide specific examples of how AWBT changed the preoperative and intraoperative management of our surgical patients. Consequently, AWBT is now considered for all patients at our institution who are undergoing intracerebral tumor resection, regardless of whether we suspect the lesion to be near eloquent structures or not. Given the relative nascency of AWBT in tumor surgery, many questions regarding its role and applicability remain unanswered. Further studies are needed to determine the ideal patient population in whom to employ AWBT, what are the optimal tumor characteristics for AWBT, how peritumoral edema can affect AWBT accuracy, and does the supplemental use of AWBT have any effect on gross total resection or reoperation rates. The current body of evidence is largely predicated on case-control and cohort studies. In order to further delineate the role of AWBT in clinical practice, the neurosurgical community will benefit from prospective, randomized trials undertaken in well-defined patient populations.
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